Skip to main content
Clinical Trials/NCT02138864
NCT02138864UnknownPhase 3

Targeting Monoaminergic Neuronal Networks in the Parkinsonian Patients After Carbon Monoxide Intoxication

Chang Gung Memorial Hospital2 sites in 1 country25 target enrollmentStarted: August 1, 2013Last updated:
Conditions

Trial Snapshot

Phase
Phase 3
Sponsor
Enrollment
25
Locations
2
Primary Endpoint
Assess the regional decline in 18F-DTBZ uptake of Parkinsonism after carbon monoxide intoxication

Study Overview

Brief Summary

The study purpose is to determine the clinical values of 18F-FP-(+)-DTBZ in the diagnosis of Parkinsonism in patients with carbon monoxide intoxication, regional distribution and its correlation with clinical parameters. This study is expected to be completed in a period of 3 years.

Detailed Description

With the urbanization of Taiwanese society, there are increasing numbers of people committing suicide by charcoal burning, making carbon monoxide (CO) encephalopathy a new pandemic phenomenon. In CO related parkinsonism, the clinical features included gait disturbances, mask face, rigidities and small steps. From literature searches, the CO related parkinsonism is related to white matter damages or decline in dopamine innervations. From our previous research results, the CO related neuronal damages would started from reversible or progressive white matter demyelination. For some patients, axonopathy or gray matter atrophy developed and became irreversible. The neuronal networks in determining development of Parkinsonism required to be established.

In terms of neurotransmitter, most of the clinical data for Parkinsonism came from studies of idiopathic Parkinson's disease while the data of CO related Parkinsonism were limited to case reports. From neuropathology studies in idiopathic Parkinson's disease, dopamine deficits and decreased in monoamine transporters were observed well before the development of clinical features. Although there is linkage between CO related Parkinsonism and dopamine deficits, patients with CO intoxication had poor response to levodopa. The observation suggested the critical networks and neurotransmitters were still not well understood.

18F-FP-(+)-DTBZ is a newly developed nuclear medicine tracer for monoamine transporter. The study purpose is to determine the clinical values of 18F-FP-(+)-DTBZ in the diagnosis of Parkinsonism in patients with carbon monoxide intoxication, regional distribution and its correlation with clinical parameters. This is a three-year prospective research. For each patient, the PET will be arranged twice, with an interval of 18 months. The regional distribuation of 18F-FP-(+)-DTBZ in relation to Parkinsonism severity and regional reduction patterns longitudially will be assessed in order to understand the regional neurotoxicity and the functional progression.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
20 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Male or female age 20 years to 65 years.
  • Patients group should fulfilled diagnostic criteria of carbon monoxide intoxication
  • Patients who provide a written informed consent prior to study entry. If the patient is incapable of informed consent, the caregiver may consent on behalf of the patient (the patient must still confirm consent)

Exclusion Criteria

  • History of developmental disorders, agitated mood or a confused state that prevented either a neuropsychiatric interview or neuroimaging.
  • Unable to stay still in the PET scanner for 30 minutes.
  • History or presence of QTc prolongation. (>500msec)
  • Pregnancy and breast feeding.

Outcomes

Primary Outcomes

Assess the regional decline in 18F-DTBZ uptake of Parkinsonism after carbon monoxide intoxication

Time Frame: up to 3 years

This study will assess the brain uptake and distribution of 18F-DTBZ in 25 carbon monoxide intoxication patients with Parkinsonism. For each patient, the PET will be arranged twice, with an interval of 1.5 years.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Chang Gung Memorial Hospital
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

chiungchihchang

MD

Chang Gung Memorial Hospital

Study Sites (2)

Loading locations...

Similar Trials